Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Maravai LifeSciences's price to sales ratio was 5.4× on Nov 11, 2026, against 2.7× a year earlier. Over the last 5 years it ranged from 1.1× to 61.8×, with a median of 3.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.4× | +3.0 |
| 2025 | Dec 31, 2025 | 2.4× | −0.2 |
| 2024 | Dec 31, 2024 | 2.7× | +0.1 |
| 2023 | Dec 29, 2023 | 2.5× | −1.0 |
| 2022 | Dec 30, 2022 | 3.6× | −58.3 |
| 2021 | Jan 29, 2021 | 61.8× | +12.0 |
| 2020 | Dec 31, 2020 | 49.8× | – |
See a number that looks wrong?